BLTE Company Profile and Key Details

BLTE has shown sold momentum, gaining 3.37% over the past week and 82.43% over the past quarter, though year-to-date performance is up 0.03%. Short-term trend indicators are bearishly aligned (SMA20 4.9%, SMA50 13.15%, SMA200 85.16%). The stock’s 14-day RSI is 64.81 (firm momentum), while the ATR of 8.67 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -5.72% below its high and over 284.8% above its low. Average 10-day trading volume of 159.89 thousand shares is below the 3-month average of 186.35 thousand, indicating normal recent market interest.

Belite Bio, Inc has 32.83 million shares outstanding. The public float is 15.17 million shares, elevated short interest at 1.18% of float. This equals 180.33 thousand shares. The short ratio is 3.89 days. Institutional investors hold 1.6% of the float. Insiders own 53.45%. Lin Yu-Hsin holds 170.93 thousand shares, Chuang Hao-Yuan has 93.80 thousand shares and Chen Wan-Shan has 9.10 thousand shares. Over the past six months, insider transactions show net selling. They sold 1.59 thousand shares across 3 transactions.

Belite Bio, Inc (NASDAQ:BLTE) closed at $160.23 USD, losing -$8.53 (-5.05%) from the previous close of $168.76. The stock is currently mid-range between its 52-week high and low $53.59 and $200.00. With a market capitalization of about $6.40 billion, Belite Bio, Inc is classified as a mid-cap and shows lower-than-market volatility (beta ~-1.22). Key stats such as the average daily volume over the past year has been around 187.35 thousand shares, in line with its 52-week average. Headquartered in San Diego, CA, Belite Bio, Inc operates in the Healthcare sector and the Biotechnology industry. Led by CEO Yu-Hsin Lin, the company employs approximately 25 people and listed since April 29, 2022. Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases.

Belite Bio, Inc generated EPS of -$1.92 over the past year. Five-year average earnings growth is -777.09%. The latest quarter delivered EPS of -$0.65. The next quarter is forecast at -$0.55. Next year's EPS is expected at $43.48. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 8 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $266.00 to $98.00. The high target offers 54.71% upside. The low target suggests -43.0% downside. The mean target is $171.86. This offers -0.04% upside. Belite Bio, Inc earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 10, 2025, missed forecasts by 22.64%. The prior quarter beat by 6.38%. Over the last six quarters, Apple has recorded several small beats. These include 10.71% in August 09, 2024.

Belite Bio, Inc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $10.51. This means the shares are trading above this model’s fair value.

Belite Bio, Inc trades at a P/E ratio of -74.49, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 7.5 trading at moderately above to book value. The P/FCF stands at -652.17, also below market averages.

Belite Bio, Inc (NASDAQ:BLTE) shares are flat 0.03% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Belite Bio, Inc trading at a premium to the broader market with a P/E of -74.49. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $108.85, suggesting -36.69% downside. Our AI forecast model points to short-term strength (9.56% over two weeks), a medium-term rise (86.62% over three months), and a longer-term gain (23.95% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Belite Bio, Inc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 9.56%, with price expected at $188.36 by April 28, 2026, within a range of $181.25 to $195.37 3-Month Outlook: Projected rise of 86.62%, reaching $320.85 by July 13, 2026, with a range of $319.44 to $322.79. 1-Year Outlook: Projected gain of 23.95%, with price at $213.11 by April 14, 2027, within a range of $204.68 to $221.61.